Haisco immunology asset goes into ARCH-founded NewCo Sentivera
Illustration (decorative, not data).Summary
ARCH Venture Partners and Population Health Partners co-founded the US company Sentivera, which takes exclusive rights outside Greater China to a Haisco immunology asset; Haisco keeps Greater China rights and holds equity in Sentivera. Neither the target nor the modality has been disclosed — only that it addresses type 2 inflammatory diseases, has just received a Chinese IND, and showed anti-inflammatory activity and good safety preclinically. This is the classic NewCo playbook: the Chinese side trades the asset for cash plus equity, while a top US VC builds the team to run overseas clinical development. Upfront and equity together are less than 5% of the headline total; most of the value depends on later milestones.
Deal terms, as disclosed
Upfront and equity combined $75.89M + milestones up to $1.46B + mid-single-digit to low-double-digit royalties.
Summary of public disclosures, not investment advice. Amounts are as announced; milestone payments are contingent and may never be paid.
Related same deal type
- Novartis takes global rights to Abogen's in vivo mRNA T-cell engager ABO2203Oct 2026
- Simcere Zaiming licenses CD79a×CD19×CD3 trispecific SIM0660 to RocheSep 2026
- J&J locks up Sail Biomedicines' in vivo CAR-T with an equity stake and an acquisition optionJul 2026
- GemPharmatech and Humlab partner on global distribution of humanized mouse modelsJul 2026
Asset owners and investors: write to bd@inlightbio.com. Newsletter and report questions: contact@inlightbio.com.